Effector Therapeutics
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company that developed small-molecule cancer therapeutics targeting eIF4E-mediated translation, with lead candidate tomivosertib; the company wound down operations in 2024 after a midstage trial failure.
- Company typePublic
- Founded2012
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Effector Therapeutics firmographics
Firmographics- Name
- Effector Therapeutics
- Legal name
- eFFECTOR Therapeutics, Inc.
- Website
- https://effector.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company that developed small-molecule cancer therapeutics targeting eIF4E-mediated translation, with lead candidate tomivosertib; the company wound down operations in 2024 after a midstage trial failure.
- Ownership category
- akta.pro rank
Effector Therapeutics industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Lead Optimization & Preclinical Candidate Selection (HLAIALAB)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
Keywords
Where Effector Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Effector Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Effector Therapeutics product offering
Product offeringCore offering
eFFECTOR Therapeutics developed novel small molecule drugs targeting translation control in cancer, with its lead candidate tomivosertib designed as a selective MNK1/2 inhibitor to disrupt eIF4E-mediated tumor growth and survival pathways. The company partnered with Pfizer to advance inhibitor development and was working to address resistance mechanisms in cancer treatment.
Differentiator
Problem solved
Functional benefit
Products and services
- Tomivosertib Lead product candidate; a selective MNK1/2 inhibitor targeting eIF4E-mediated tumor growth and survival pathways, investigated for cancer treatment in clinical-stage development.
Companies that use Effector Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Effector Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Effector Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- PfizercoreCollaboration with Pfizer for developing inhibitors. The partnership focused on leveraging Pfizer's expertise alongside eFFECTOR's eIF4E translation control platform for cancer treatment development.
Scale indicators4 records
Effector Therapeutics competitors and assessment
Company assessmentDirect peers
- Black Diamond Therapeutics: Clinical-stage precision oncology company developing small-molecule therapies against oncogenic mutations. Highly comparable as a public, micro-cap clinical-stage oncology biotech with platform-based small-molecule discovery.
- Relay Therapeutics: Clinical-stage precision oncology company using a motion-based drug design platform to develop small-molecule inhibitors against oncogenic targets. Comparable as a clinical-stage small-molecule oncology company pursuing differentiated mechanisms.
- Erasca: Clinical-stage precision oncology company focused on RAS/MAPK pathway small-molecule inhibitors. Comparable as a clinical-stage, public oncology biotech with single-mechanism focus and binary readouts.
- Tango Therapeutics: Clinical-stage oncology company developing small-molecule drugs targeting synthetic lethal vulnerabilities in cancer. Comparable as a public clinical-stage oncology biotech leveraging a differentiated mechanistic platform.
Broad incumbents
- Blueprint Medicines: Established clinical and commercial-stage precision oncology company developing kinase inhibitors. Comparable as a broader kinase/translation-targeting oncology player with operational scale beyond eFFECTOR's niche.
- Mirati Therapeutics: Precision oncology company developing targeted small-molecule inhibitors (acquired by Bristol Myers Squibb in 2024). Comparable as a clinical-stage precision oncology small-molecule player with a similarly concentrated pipeline profile.
- Constellation Pharmaceuticals: Clinical-stage epigenetics-based oncology company (acquired by MorphoSys in 2021). Comparable as a public clinical-stage oncology company with a single platform mechanism and binary clinical readouts.
Emerging players
- Kymera Therapeutics: Clinical-stage biotech developing targeted protein degradation (TLR/IRAK, etc.) small molecules in oncology and immunology. Comparable as a public clinical-stage small-molecule oncology biotech with a novel mechanism platform.
- Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company with an oncology pipeline. Comparable as a publicly listed clinical-stage biotech pursuing novel mechanism discovery, though differentiated by its AI-discovery approach.
- Pimera (private): Private oncology drug discovery company pursuing precision oncology programs. Comparable as a small clinical/preclinical-stage oncology company with platform-based small-molecule discovery in a similar stage profile.
Market position
Customer concentration
Effector Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Effector Therapeutics leadership team
Management profileNumber of profiles
Effector Therapeutics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Effector Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Effector Therapeutics
What does Effector Therapeutics do?
eFFECTOR Therapeutics developed novel small molecule drugs targeting translation control in cancer, with its lead candidate tomivosertib designed as a selective MNK1/2 inhibitor to disrupt eIF4E-mediated tumor growth and survival pathways. The company partnered with Pfizer to advance inhibitor development and was working to address resistance mechanisms in cancer treatment.
Is Effector Therapeutics a public or private company?
Effector Therapeutics is a public company. It is classified as public and is currently closed.
When was Effector Therapeutics founded?
Effector Therapeutics was founded in 2012. It employs 11 to 50 people.
Where is Effector Therapeutics based?
Effector Therapeutics is headquartered in San Diego, United States, in the North America region.
Who are Effector Therapeutics's main competitors?
Direct peers on record are Black Diamond Therapeutics, Relay Therapeutics, Erasca and Tango Therapeutics. Broad incumbents are Blueprint Medicines, Mirati Therapeutics and Constellation Pharmaceuticals. Emerging players are Kymera Therapeutics, Recursion Pharmaceuticals and Pimera (private).
Does Effector Therapeutics have an API?
No public API is recorded for Effector Therapeutics.
What industry is Effector Therapeutics in?
Effector Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.